PopVax

About PopVax

PopVax is an Indian full-stack biotechnology company developing novel mRNA vaccines and therapeutics using computational protein design. Our first vaccine is a next-generation COVID-19 booster which will enter a first-in-human Phase I clinical trial in the U.S. early next year – this vaccine is intended to broaden protection against both current and predicted future SARS-CoV-2 variants, reducing the possibility of a new mutation in the virus suddenly causing another massive wave of infection.

We are now a team of 70+ across our computational design, machine learning, molecular & cell biology, immunology, mRNA delivery, analytical method development, GMP production, quality, and regulatory teams, all of which are hiring. Our experimental work is based at the RNA Foundry, PopVax’s integrated R&D and GMP-capable clinical dose production facility in Hyderabad.

The name PopVax is a portmanteau of the phrase population-scale vaccines. It represents our commitment to building a platform for cutting-edge vaccine development and production whose benefits are available at the same time to the entire global population, rather than just people lucky enough to live in rich countries. Over the next decade, our mission is to develop and distribute vaccines that save one million lives each year across the world that would otherwise be lost to infectious diseases.

Our work to date has been funded primarily via project agreements with the Bill & Melinda Gates Foundation and Vitalik Buterin's public health & biosecurity organization Balvi.

Feel free to reach out to us via email (contact@popvax.com) or visit our website for more information.